An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function

Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied onl...

Full description

Bibliographic Details
Main Authors:	Shyam Patel, Jennifer Andres, Kamran Qureshi
Format:	Article
Language:	English
Published:	Hindawi Limited 2016-01-01
Series:	Case Reports in Medicine
Online Access:	http://dx.doi.org/10.1155/2016/3191089

Similar Items

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01)

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
by: Sachiko Omotani, et al.
Published: (2020-04-01)

Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)
by: Sergio Vicente-Sánchez, et al.
Published: (2017-03-01)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018-07-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019-03-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
by: Peter Buggisch, et al.
Published: (2019-01-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
by: R Jha, et al.
Published: (2016-01-01)

Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management
by: Zaver, Himesh, et al.
Published: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017-03-01)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
by: Shih-Jer Hsu, et al.
Published: (2020-03-01)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
by: Giovanni Covini, et al.
Published: (2018-10-01)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
by: Jennifer S. Husson, MD, MPH, et al.
Published: (2017-12-01)

Rhabdomyolysis induced by co-administration of fluvastatin and colchicine
by: Filippo M. Sarullo, et al.
Published: (2015-12-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Simultaneous chromatographic analysis of Sofosbuvir/Ledipasvir in their combined dosage form: an application to green analytical chemistry
by: Ahmed Hemdan, et al.
Published: (2019-12-01)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
by: Patrick R. Brown, et al.
Published: (2018-10-01)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
by: William Stokes, et al.
Published: (2017-01-01)

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience
by: Mete Akin, et al.
Published: (2018-06-01)

Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction
by: Khan MW, et al.
Published: (2016-04-01)

Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report
by: Alireza Heidari Bakavoli, et al.
Published: (2020-09-01)

The efficacy and safety of sofosbuvir/ledipasvir therapy in patients on long-term hemodialysis with hepatitis C virus infection
by: G Li Cavoli, et al.
Published: (2018-01-01)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
by: Jesús Quintero, et al.
Published: (2019-03-01)

Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
by: Elazzazy S, et al.
Published: (2012-09-01)

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
by: Xue Yang, et al.
Published: (2021-07-01)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
by: Catherine A Chappell, MD, et al.
Published: (2020-09-01)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
by: Vincent Alcazer, et al.
Published: (2018-12-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
by: Yuki Tahata, et al.
Published: (2018-08-01)

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone
by: Jessica Laird, BA, et al.
Published: (2020-12-01)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
by: Gregory D Huhn, et al.
Published: (2020-01-01)

Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report
by: Meghan L. McPhie, et al.
Published: (2021-07-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)

Cannot write session to /tmp/vufind_sessions/sess_vlq4ablm4uinb97siqeuu4c27r